Healthcare / BiotechnologyNasdaqCM
$8.11
+0.04 (+0.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-65.7M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$55M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-62.7%
↓Gross Margin
N/A
•Debt/Equity
0.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-71.4M · FCF $-46.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | $0.00 | $138000.00 |
| Net Income | $-71.4M | $-71.4M | $-74.1M | $-156.1M | $-223.2M | $-156.8M | $-37.7M |
| EBITDA | $-65.8M | $-65.8M | $-62.5M | $-147.1M | $-217.4M | $-152.8M | $-33.4M |
| EPS | — | — | -11.39 | -24.00 | -34.40 | -29.60 | -47.20 |
| Operating Margin | — | — | — | — | — | — | -24379.7% |
| Net Margin | — | — | — | — | — | — | -27346.4% |
| Balance Sheet | |||||||
| Debt/Equity | 0.75 | 0.75 | 0.51 | 0.38 | 0.22 | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-46.6M | $-46.6M | $-65.7M | $-102.7M | $-264.8M | $-180.0M | $-80.4M |
| Returns | |||||||
| ROE | -62.7% | -62.7% | -43.8% | -69.1% | -61.4% | -28.2% | 95.3% |
| Valuation | |||||||
| P/B | 0.48 | 0.48 | 0.79 | 0.22 | 0.23 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | — | — | -100.0% | — |
| EPS Growth | — | — | 52.5% | 30.2% | — | 37.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-69.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-11.39 → n/d
Residual
-69.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.